Evolution of clinical trial endpoints in chronic myeloid leukemia: Efficacious therapies require sensitive monitoring techniques

Raoul Tibes, Ruben A. Mesa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The efficacy of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has brought treatment response assessment to the molecular level. Clinical trials endpoints for newer TKIs - such as major and complete molecular response - reflect the trend toward more-sensitive disease detection and deeper responses. Practice guidelines now formally define levels of response and link response benchmarks to outcome and treatment guidance. Efforts are ongoing to harmonize the methodology and terminology used to characterize molecular response. This review discusses the evolution of CML clinical trial endpoints in response to current therapeutic and monitoring modalities, and the implications of achieving molecular endpoints.

Original languageEnglish (US)
Pages (from-to)664-671
Number of pages8
JournalLeukemia Research
Volume36
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Clinical Trials
Benchmarking
Practice Guidelines
Terminology
Therapeutics

Keywords

  • Chronic myeloid leukemia
  • Dasatinib
  • Endpoints
  • Imatinib
  • Molecular monitoring
  • Nilotinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Evolution of clinical trial endpoints in chronic myeloid leukemia : Efficacious therapies require sensitive monitoring techniques. / Tibes, Raoul; Mesa, Ruben A.

In: Leukemia Research, Vol. 36, No. 6, 06.2012, p. 664-671.

Research output: Contribution to journalArticle

@article{3871d1feec0b406aa555a80644fbdc44,
title = "Evolution of clinical trial endpoints in chronic myeloid leukemia: Efficacious therapies require sensitive monitoring techniques",
abstract = "The efficacy of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has brought treatment response assessment to the molecular level. Clinical trials endpoints for newer TKIs - such as major and complete molecular response - reflect the trend toward more-sensitive disease detection and deeper responses. Practice guidelines now formally define levels of response and link response benchmarks to outcome and treatment guidance. Efforts are ongoing to harmonize the methodology and terminology used to characterize molecular response. This review discusses the evolution of CML clinical trial endpoints in response to current therapeutic and monitoring modalities, and the implications of achieving molecular endpoints.",
keywords = "Chronic myeloid leukemia, Dasatinib, Endpoints, Imatinib, Molecular monitoring, Nilotinib, Tyrosine kinase inhibitors",
author = "Raoul Tibes and Mesa, {Ruben A.}",
year = "2012",
month = "6",
doi = "10.1016/j.leukres.2012.02.027",
language = "English (US)",
volume = "36",
pages = "664--671",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Evolution of clinical trial endpoints in chronic myeloid leukemia

T2 - Efficacious therapies require sensitive monitoring techniques

AU - Tibes, Raoul

AU - Mesa, Ruben A.

PY - 2012/6

Y1 - 2012/6

N2 - The efficacy of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has brought treatment response assessment to the molecular level. Clinical trials endpoints for newer TKIs - such as major and complete molecular response - reflect the trend toward more-sensitive disease detection and deeper responses. Practice guidelines now formally define levels of response and link response benchmarks to outcome and treatment guidance. Efforts are ongoing to harmonize the methodology and terminology used to characterize molecular response. This review discusses the evolution of CML clinical trial endpoints in response to current therapeutic and monitoring modalities, and the implications of achieving molecular endpoints.

AB - The efficacy of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) has brought treatment response assessment to the molecular level. Clinical trials endpoints for newer TKIs - such as major and complete molecular response - reflect the trend toward more-sensitive disease detection and deeper responses. Practice guidelines now formally define levels of response and link response benchmarks to outcome and treatment guidance. Efforts are ongoing to harmonize the methodology and terminology used to characterize molecular response. This review discusses the evolution of CML clinical trial endpoints in response to current therapeutic and monitoring modalities, and the implications of achieving molecular endpoints.

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Endpoints

KW - Imatinib

KW - Molecular monitoring

KW - Nilotinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84859871645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859871645&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.02.027

DO - 10.1016/j.leukres.2012.02.027

M3 - Article

C2 - 22459332

AN - SCOPUS:84859871645

VL - 36

SP - 664

EP - 671

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 6

ER -